The company is evaluating an additional application for CyPath Lung that could complement CT imaging when monitoring lung ...

Cizzle Bio Inc., a biotechnology company advancing biomarker blood tests for early cancer detection, has announced the publication of new peer-reviewed research supporting the clinical utility of the ...

The combination of artificial intelligence (AI)-based nodule detection software and a structured, navigator-tracked follow-up clinic helped identify early-stage lung cancer in a p ...

BioAffinity Technologies (BIAF) stock rallied 55% after revealing CyPath Lung's potential to monitor lung cancer survivors ...

Computational pathology has recently emerged as a field that combines digital pathology, medical imaging, and artificial ...

The next breakthrough in cancer screening is emerging from the convergence of artificial intelligence and canine biology. That’s the thesis behind SpotitEarly, a startup that recently launched in the ...

Our spotlight call highlights key areas where dedicated research efforts to address inequalities in cancer early detection and diagnosis can improve patient outcomes.

Liquid biopsy encompasses a variety of molecular approaches to detect circulating tumor DNA (ctDNA) and has become a powerful tool in the diagnosis and treatment of solid tumors. Current applications ...

Some claim the new multi-cancer detection tests will “revolutionize” cancer screening. Others fear the “worried well” will succumb to slick marketing and subpar tests and overwhelm both primary care ...

SAN ANTONIO, September 01, 2026--bioAffinity Technologies is advancing the application of its CyPath Lung test for ...